Table 1 Characteristics of study participants at time of inclusion
All participants | Individuals receiving control first and rose hip second | Individuals receiving rose hip first and control second | |
|---|---|---|---|
Age (years) | 57±2 (37–75)a | 59±3 (42–75) | 55±3 (37–71) |
Female (n=22) | 59±2 (42–75) | 61±3 (42–75) | 57±3 (44–69) |
Male (n=9) | 52±4 (37–71) | 53±5 (48–67) | 52±7 (37–71) |
Body weight (kg) | 102.9±2.8 (80.4–135.8) | 95.4±3.8 (80.4–129.5) | 110.9±3.3 (83.6–135.8) |
BMI (kg/m2) | 35.3±0.6 (29.5–44) | 35.5±0.6 (29.5–38.9) | 37.2±0.9 (31.5–44) |
Systolic BP (mm Hg) | 129±3 (105–170) | 130±3 (105–152) | 128±4 (105–170) |
Diastolic BP (mm Hg) | 77±2 (60–110) | 74±1 (60–84) | 80±3 (60–110) |
FP-glucose (mmol/l) | 5.6±0.1 (4.5–7.3) | 5.4±0.1 (4.5–6.8) | 5.9±0.2 (4.5–7.3) |
FP-insulin (mIU/l) | 11.4±0.7 (6–22) | 10.6±0.8 (6–17) | 12.3±1.2 (6–22) |
FP-cholesterol (mmol/l) | 5.4±0.2 (3.8–8.9) | 5.6±0.4 (3.8–8.9) | 5.1±0.2 (4.0–6.6) |
FP-LDL cholesterol (mmol/l) | 3.2±0.2 (1.6–6.4) | 3.5±0.3 (2.1–6.4) | 2.9±0.2 (1.6–4.1) |
FP-HDL cholesterol (mmol/l) | 1.4±0.07 (0.6–2.4) | 1.4±0.09 (0.6–2.2) | 1.4±0.1 (0.7–2.4) |
FP-TG (mmol/l) | 1.6±0.1 (0.7–3.3) | 1.6±0.2 (0.7–3.1) | 1.6±0.2 (0.8–3.3) |
P-ASAT (μkat/l) | 0.46±0.05 (0.22–1.90) | 0.48±0.09 (0.22–1.90) | 0.43±0.02 (0.29–0.61) |
P-ALAT (μkat/l) | 0.49±0.07 (0.19–2.30) | 0.52±0.12 (0.19–2.30) | 0.47±0.05 (0.25–0.84) |
P-ALP (μkat/l) | 1.16±0.05 (0.25–0.84) | 1.24±0.06 (0.76–1.70) | 1.08±0.07 (0.52–1.60) |
P-GT (μkat/l) | 0.56±0.07 (0.22–1.70) | 0.49±0.08 (0.22–1.70) | 0.62±0.10 (0.25–1.50) |
P-bilirubin (μmol/l) | 9±1 (3–21) | 10±1 (4–21) | 7±1 (3–16) |
